Surrozen, Inc. has recently filed an update with the SEC that reveals a notable shift in its shareholder structure. The filing indicates that Integrated Core Strategies (US) LLC and Millennium Management LLC have reduced their combined ownership in the company, which could reflect changing investment strategies in the biological products sector.

This filing, dated November 13, 2026, is classified as a Schedule 13G/A, which is typically used to report changes in beneficial ownership of securities. The significance of this update lies in the potential implications for Surrozen's future and the broader biological products industry.

Background

Surrozen, Inc. is a Delaware-based company primarily engaged in the development of biological products, specifically those that do not include diagnostic substances. The company is listed on the Nasdaq under the ticker SRZN. Surrozen operates within the SIC classification of 2836, which encompasses biological products.

Recent filings from Surrozen include a Schedule 13G/A on November 13, 2026, a Form 10-Q on November 9, 2026, and an 8-K on the same date. These filings indicate ongoing activity and reporting requirements as the company navigates its operational landscape.

What the Filing Says

The recent Schedule 13G/A filing reveals that the reporting entities, including Integrated Core Strategies (US) LLC and Millennium Management LLC, have ceased to beneficially own more than 5% of Surrozen's common stock. Specifically, Integrated Core Strategies holds 557,450 shares, representing 2.9% of the class, while Millennium Management holds 615,730 shares, accounting for 3.2%.

The filing states, "As of the date hereof, the reporting persons have ceased to beneficially own more than 5 percent of the class of securities." This marks a significant change in the investment landscape for Surrozen, indicating a potential shift in strategy by these institutional investors.

Impact

This change in ownership could affect various stakeholders, including existing shareholders, potential investors, and the management team at Surrozen. The reduction in ownership by significant institutional investors may influence market perceptions and investor confidence in the company's direction.

Additionally, the broader biological products industry may take note of this development, as it could signal shifting trends in investment approaches and shareholder engagement strategies. Companies within the same SIC classification may observe how Surrozen adapts to these changes.

What's Next

The filing does not specify what happens next for Surrozen, Inc. However, stakeholders will likely be keen to monitor future filings and developments as the company continues to navigate its operational and financial landscape.